Should EOAD patients be included in clinical trials?

por Szigeti, Kinga, Doody, Rachelle S
Publicado 2011

Should persons with autosomal dominant AD be included in clinical trials? Authors' response

por Szigeti, Kinga, Doody, Rachelle S
Publicado 2011

Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment

por Pavlik, Valory N, Doody, Rachelle S
Publicado 2011

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report

por Spiegel, René, Doody, Rachelle S, Hendrix, Suzanne, Kahle-Wrobleski, Kristin
Publicado 2013

Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer's Disease: Comparison of Efficacy and Effecti...

por Atri, Alireza, Rountree, Susan D., Lopez, Oscar L., Doody, Rachelle S.
Publicado 2012

Predicting progression of Alzheimer's disease

por Doody, Rachelle S, Pavlik, Valory, Massman, Paul, Rountree, Susan, Darby, Eveleen, Chan, Wenyaw
Publicado 2010

Correction: Predicting progression of Alzheimer's disease

por Doody, Rachelle S, Pavlik, Valory, Massman, Paul, Rountree, Susan, Darby, Eveleen, Chan, Wenyaw
Publicado 2010

Factors that influence survival in a probable Alzheimer disease cohort

por Rountree, Susan D, Chan, Wenyaw, Pavlik, Valory N, Darby, Eveleen J, Doody, Rachelle S
Publicado 2012

Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease

por Liang, Fu-Wen, Chan, Wenyaw, Chen, Ping-Jen, Zimmerman, Carissa, Waring, Stephen, Doody, Rachelle
Publicado 2016

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

por Rountree, Susan D, Chan, Wenyaw, Pavlik, Valory N, Darby, Eveleen J, Siddiqui, Samina, Doody, Rachelle S
Publicado 2009

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

por Doody, Rachelle S., Demirovic, Jasenka, Ballantyne, Christie M., Chan, Wenyaw, Barber, Robert, Powell, Suzanne, Pavlik, Valory
Publicado 2015

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

por Sabbagh, Marwan, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Liu, Liang, Mackell, Joan, Fain, Randi
Publicado 2013

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

por Ferris, Steven, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Sabbagh, Marwan, Liu, Liang, Mackell, Joan, Fain, Randi
Publicado 2013

A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI

por O'Bryant, Sid E., Xiao, Guanghua, Barber, Robert, Huebinger, Ryan, Wilhelmsen, Kirk, Edwards, Melissa, Graff-Radford, Neill, Doody, Rachelle, Diaz-Arrastia, Ramon
Publicado 2011

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

por Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Publicado 2015

The dementia and disability project in Thai elderly: rational, design, methodology and early results

por Senanarong, Vorapun, Harnphadungkit, Kamolthip, Poungvarin, Niphon, Vannasaeng, Sathit, Chongwisal, Samut, Chakorn, Tipa, Jamjumrus, Piyanuch, Raksthaput, Atthapon, Chaichanettee, Sinisa, Aoonkaew, Nattapol, Udompunthurak, Suthipol, Doody, Rachelle S, Cummings, Jeffrey L
Publicado 2013

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

por Doody, Rachelle S, Raman, Rema, Sperling, Reisa A, Seimers, Eric, Sethuraman, Gopalan, Mohs, Richard, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Sun, Xiaoying, Ernstrom, Karin, Thomas, Ronald G, Aisen, Paul S
Publicado 2015

Alzheimer’s disease progression by geographical region in a clinical trial setting

por Henley, David B, Dowsett, Sherie A, Chen, Yun-Fei, Liu-Seifert, Hong, Grill, Joshua D, Doody, Rachelle S, Aisen, Paul, Raman, Rema, Miller, David S, Hake, Ann M, Cummings, Jeffrey
Publicado 2015

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

por Bateman, Randall J., Cummings, Jeffrey, Schobel, Scott, Salloway, Stephen, Vellas, Bruno, Boada, Mercè, Black, Sandra E., Blennow, Kaj, Fontoura, Paulo, Klein, Gregory, Assunção, Sheila Seleri, Smith, Janice, Doody, Rachelle S.
Publicado 2022

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

por Klein, Gregory, Delmar, Paul, Voyle, Nicola, Rehal, Sunita, Hofmann, Carsten, Abi-Saab, Danielle, Andjelkovic, Mirjana, Ristic, Smiljana, Wang, Guoqiao, Bateman, Randall, Kerchner, Geoffrey A., Baudler, Monika, Fontoura, Paulo, Doody, Rachelle
Publicado 2019